MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Coherus Biosciences Inc

Gesloten

SectorGezondheidszorg

0.77 -4.94

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.74

Max

0.81

Belangrijke statistieken

By Trading Economics

Inkomsten

-40M

-51M

Verkoop

-17M

54M

K/W

Sectorgemiddelde

3.363

63.778

EPS

-0.28

Winstmarge

-93.632

Werknemers

228

EBITDA

-40M

-44M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+753.66% upside

Dividenden

By Dow Jones

Volgende Winsten

8 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-19M

97M

Vorige openingsprijs

5.71

Vorige sluitingsprijs

0.77

Nieuwssentiment

By Acuity

50%

50%

167 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Coherus Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 apr 2025, 22:38 UTC

Populaire aandelen

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 apr 2025, 21:53 UTC

Marktinformatie

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 apr 2025, 21:44 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 apr 2025, 21:00 UTC

Top Nieuws

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 apr 2025, 20:52 UTC

Marktinformatie

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 apr 2025, 20:52 UTC

Top Nieuws

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 apr 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 apr 2025, 20:48 UTC

Top Nieuws

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 apr 2025, 20:45 UTC

Top Nieuws

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 apr 2025, 20:32 UTC

Top Nieuws

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 apr 2025, 20:21 UTC

Top Nieuws

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 apr 2025, 20:00 UTC

Top Nieuws

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 apr 2025, 19:51 UTC

Marktinformatie

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 apr 2025, 19:37 UTC

Top Nieuws

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 apr 2025, 19:32 UTC

Marktinformatie

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 apr 2025, 19:28 UTC

Top Nieuws

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 apr 2025, 19:15 UTC

Marktinformatie

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 apr 2025, 19:12 UTC

Top Nieuws

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 apr 2025, 19:11 UTC

Marktinformatie

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 apr 2025, 19:09 UTC

Marktinformatie

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 apr 2025, 19:09 UTC

Top Nieuws

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 apr 2025, 19:00 UTC

Marktinformatie

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 apr 2025, 18:53 UTC

Marktinformatie

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 apr 2025, 18:51 UTC

Marktinformatie

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 apr 2025, 18:44 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

4 apr 2025, 18:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 apr 2025, 18:44 UTC

Marktinformatie

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 apr 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 apr 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 apr 2025, 18:39 UTC

Marktinformatie

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Peer Vergelijking

Prijswijziging

Coherus Biosciences Inc Prognose

Koersdoel

By TipRanks

753.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7 USD  753.66%

Hoogste 7 USD

Laagste 7 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Coherus Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.79 / 0.8386Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

167 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.